Campylobacter Vaccines and Methods of use
OwnerJohn A. Ellis, George Steven Krakowka +1inventors
InventorsJohn A. Ellis, George Steven Krakowka, Kathleen Anne McIntosh
Life of this patent
Estimating the term…
Abstract
Porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused by Campylobacter pathogens, such as C. coli are described, as well as methods of identifying vaccines and compounds for treating and/or preventing Campylobacter infection using the animal models. Also described are methods of preventing Campylobacter infection in swine, such as infection caused by C. coli, using immunogenic proteins and nucleic acids derived from Campylobacter pathogens, such as C. coli.
Claims29
A method of treating or preventing Campylobacter infection in a porcine subject comprising administering to said subject a therapeutically effective amount of a composition comprising at least one Campylobacter immunogen.
The method of 1, wherein the composition further comprises an adjuvant.
The method of 1, wherein the composition is administered orally.
A method for infecting a gnotobiotic piglet with a porcine isolate of Campylobacter, said method comprising:
- (a) isolating Campylobacter from a porcine subject;
- and
- (b) administering a dose of the Campylobacter isolate to said gnotobiotic piglet in an amount sufficient to cause Campylobacter infection.
A method for evaluating the ability of a vaccine to prevent Campylobacter infection comprising:
- (a) administering to a porcine subject a candidate vaccine;
- (b) exposing the porcine subject from step (a) to a Campylobacter isolate in an amount sufficient to cause infection in an unvaccinated subject;
- and
- (c) observing the incidence of Campylobacter infection in the porcine subject, thereby evaluating the ability of the candidate vaccine to prevent Campylobacter infection.
A method of producing a porcine animal model of gastroesophageal ulceration (GEU) of the pars esophagea, said method comprising:
- (a) isolating Campylobacter from a porcine subject;
- (b) exposing a gnotobiotic piglet to the Campylobacter isolate in an amount sufficient to cause infection in said piglet;
- and
- (c) feeding said infected piglet a milk-replacement diet that contains a dietary source of fermentable carbohydrate under conditions sufficient for producing GEU of the pars esophagea.
A method of producing a porcine animal model of gastroesophageal ulceration (GEU) of the pars esophagea, said method comprising:
- (a) isolating C. coli from a porcine subject;
- (b) orally administering 107-109 colony forming units of the C. coli isolate to a gnotobiotic piglet in order to cause C. coli infection;
- and
- (c) feeding said infected piglet a milk-replacement diet that contains corn syrup as a fermentable source of carbohydrate under conditions sufficient for producing GEU of the pars esophagea.
A method of identifying a compound capable of treating Campylobacter infection, said method comprising:
- (a) exposing a gnotobiotic piglet to a Campylobacter isolate in an amount sufficient to cause infection in said piglet;
- (b) delivering a compound or series of compounds to said infected piglet;
- and
- (c) examining the piglet from step (b) for the presence or loss of Campylobacter bacteria and/or the development, inhibition, or amelioration of ulcer or tumor formation relative to an untreated Campylobacter-infected gnotobiotic piglet.
(canceled)
(canceled)
A method for preventing food-borne transmission of Campylobacter pathogens to humans due to consumption of pork, said method comprising administering to a porcine subject a therapeutically effective amount of a composition comprising at least one Campylobacter immunogen.
Dependencies are inferred from the claim text.